The idea is biologically plausible and historically grounded — and it reframes how we think about the origin of pandemics.

When scientists engineer a better way to fight the flu, they often begin with nature’s own defenses. That’s what a new study ...

New research by scientists at the University of Toronto and the Structural Genomics Consortium has deepened our understanding ...

Annual flu shots could become a thing of the past under a new vaccine strategy developed and tested by University of Nebraska ...

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows.

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows. The new molecule combines the specificity of a mature flu fighter with the ...

PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech” or the "Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and infectious ...

While the risk of contracting and dying from the H5N1 avian flu remains low for humans, researchers continue to hunt for ...

The Global Virus Network, a group that represents virologists from more than 40 countries, has called on governments around ...

While current influenza vaccines primarily target the variable hemagglutinin protein, the slower-evolving neuraminidase presents a promising target for the development of new vaccines providing ...

H5N1 is a subtype of the Influenza A virus, named after two surface proteins: hemagglutinin (H) and neuraminidase (N). While there are several subtypes (such as H1N1 or H3N2), H5N1 is particularly ...